Prudential PLC vs Vir Biotechnology Inc. Common Stock — how do they compare? Prudential PLC trades at $23.69 (market cap $29.00B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Prudential PLC is far larger — about 16.1× Vir Biotechnology Inc. Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| PUK | VIR | |
|---|---|---|
Market Cap | $29.00B | $1.80B |
Volume | 1,133,946 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $33.61 | $11.78 |
52-Week Low | $23.54 | $5.12 |
Typical Hold Time | 119 Days | 0 Days |
Enterprise Value | $28.54B | $1.36B |
Dividend Yield | 2.33% | — |
Signals from Pluang's Aura AI — not financial advice
Prudential Public Limited Company (PUK) trades at $23.81, down 0.25% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company demonstrates strong fundamentals with $27.39B revenue in 2025, 12.27% net income margin, and attractive valuation metrics including an 8.38 P/E ratio. Recent earnings show two beats and two misses in the last four quarters, while analyst sentiment remains moderately positive with 50% buy ratings.
PUK presents a compelling value opportunity with strong profitability and growth in Asian markets, though near-term technical weakness and emerging market exit execution risks warrant caution. The stock's current valuation discount to peers and consistent dividend payments provide downside protection, while strategic refocusing on core markets could drive long-term shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →